Positive on Indoco Remedies: Mahantesh Sabarad

Mahantesh Sabarad of SBI Capital Securities told CNBC-TV18, "On the pharmaceutical sector, we have a clutch of small to midcap kind of pharmaceutical companies where we would remain positive. Indoco Remedies is one of them. However, typically in the large pharmaceutical space and which I have enumerated even in the past that we have been very cautious simply because there is a lot of FDA issues most of the largecap pharmaceutical companies have faced." "Fortunately, of all these largecap pharmaceutical stocks, the only one which seems to be a little away from the FDA issues is Lupin. However, even if I name Lupin, the stock is slightly expensive than what we would have been comfortable with," he said.